about
New strategies for allergen T cell epitope identification: going beyond IgEEfficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method.Anti-inflammatory cytokines in asthma and allergy: interleukin-10, interleukin-12, interferon-gamma.Mechanisms of interleukin-10-mediated immune suppression.Current status of interleukin-10 and regulatory T-cells in cancerA novel and well tolerated mite allergoid subcutaneous immunotherapy: evidence of clinical and immunologic efficacyImmune mechanisms of allergen-specific sublingual immunotherapy.The future of vaccination as a treatment strategy in dermatological diseases.New concepts of cytokines in asthma: is the Th2/Th1 paradigm out the window?Genes of tolerance.Allergy vaccines--new approaches to an old concept.Medicinal application of long synthetic peptide technology.13-year overview of serious adverse drug reactions following subcutaneous specific immunotherapy with a chemically modified allergen preparation.Modulation of the humoral response to Dermatophagoides pteronyssinus allergens in BALB/c mice by extract modification and adjuvant use.Immunology of Bee Venom.Single cell assessment of allergen-specific T cell responses with MHC class II peptide tetramers: methodological aspects.Depigmented allergoids reveal new epitopes with capacity to induce IgG blocking antibodies.A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections.The recombinant major allergen of Parietaria judaica and its hypoallergenic variant: in vivo evaluation in a murine model of allergic sensitization.Interleukin-10, T regulatory cells and specific allergy treatment.Distinct characteristics of seasonal (Bet v 1) vs. perennial (Der p 1/Der p 2) allergen-specific CD4(+) T cell responses.Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children.Venom immunotherapy induces monocyte activation.Hymenoptera venom allergyCellular immune responses to ovalbumin and house dust mite in egg-allergic children
P2860
Q26824787-F5E99A30-7DCF-40D0-A1B7-672392267E5CQ33255883-28717C0C-E4F3-4F0B-B782-BC94E21C3098Q34281214-0B81EB77-0F48-4E7C-B81E-17D9E01B9622Q34285968-035E7AA8-A975-4964-A3F3-7715EEB581BEQ34374026-A2EC1D5E-6699-4B64-9938-42EB280B8110Q34442836-17065675-4596-4616-B205-D0EA5644E80CQ34484071-2F265716-BA93-44A2-A0DC-C947E67BCE32Q35015879-2ACFE893-97A7-4FB2-AE3B-C577F4F19E05Q35589508-C5F96C24-09B8-446A-8285-DA16A279F020Q35855013-F9FB96DE-7492-490C-9E79-F3CE5E32ABCFQ35873779-19E0EDE9-A2C7-47BD-854D-F7A2B7F9618BQ35907030-D7E12FC9-CA1D-41D8-80AF-7E38A62E75B9Q36688498-8A5FA352-C00F-4D4C-82F8-76ED9E8DC891Q38329952-58C80984-172C-4F7D-867D-211EF6022469Q39096069-98D9CF3D-0028-45C1-9CFC-77DFF486614AQ40023296-CC87F592-3B56-4309-BE6C-1542D8C0F0F2Q42923733-43380E01-1AF6-4ED0-89CC-FD6FAC472B27Q43650387-FBA09863-2C86-49BC-A857-468599FE558CQ47988432-4767C13C-5A04-4807-8CBF-E69EFF6D6579Q47988592-418D604F-2A30-4683-AEA0-440E6A0FB57DQ51029588-088DA7A8-B3C6-407E-83BB-FDA2603627F4Q51575029-F37FFFC1-E154-4D91-B364-57CF05111BCFQ52590838-209273FF-1EA4-4144-9DC7-EE50555B91EDQ58617695-802BE0AD-C6B7-40D4-8E3F-BFE56DB5AD82Q59310566-95A21C3C-7E75-46DB-90A2-A0BFA446412D
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Mechanisms of allergen-specific immunotherapy.
@ast
Mechanisms of allergen-specific immunotherapy.
@en
type
label
Mechanisms of allergen-specific immunotherapy.
@ast
Mechanisms of allergen-specific immunotherapy.
@en
prefLabel
Mechanisms of allergen-specific immunotherapy.
@ast
Mechanisms of allergen-specific immunotherapy.
@en
P2860
P1433
P1476
Mechanisms of allergen-specific immunotherapy.
@en
P2093
P2860
P304
P356
10.1034/J.1398-9995.2000.00120.X
P577
2000-06-01T00:00:00Z